Vincerx Pharma Announces Presentations at the American Society of Hematology Annual Meeting

PALO ALTO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that two abstracts related to the Company’s selective PTEFb/CDK9 inhibitor, VIP152, program have been accepted for presentation at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting, to be held December 11-14, 2021 in Atlanta, GA. The following abstracts were published today and are now available on the ASH website at www.hematology.org.

   
VIP152, a selective CDK9 inhibitor, induces complete regression of high-grade B-cell lymphoma (HGBL) models and depletion of short-lived oncogenic driver transcripts, MYC and MCL1, with a once weekly schedule. (Abstract #1192)
   
Session Name: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms
   
Date: Saturday, December 11, 2021
   
Time: Poster viewing 9:00am-7:30pm; presenters available 5:30-7:30pm ET
   
Location: Hall B5
   
VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia (Abstract #270)
   
Session Name: Chemical Biology and Experimental Therapeutics
   
Date: Saturday, December 11, 2021
   
Time: Oral Presentation at 3:15 ET
   
Location: Georgia World Congress Center, C108-C109
   

About Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (“Vincerx”) is a clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients. Vincerx’s current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation platform, which includes next-generation antibody-drug conjugates and innovative small molecule drug conjugates.

Contact Information

Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com


Primary Logo

Back to news